| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2023-01-24 | Biosergen | Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-01-24 | Biosergen | Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
Pressreleaser |
Biosergen AB: Biosergen – Svampdödare med potential – Mangold Insight AnalysBiosergens läkemedelskandidat, BSG005 genomgår fas 1-studier och har hittills visat sig säker utan toxisk påverkan på njure eller lever, något som är vanligt hos konkurrerande svampdödande läkemedel. Att få fram ett effektivt och säkert behandlingsalternativ kommer göra BSG005 till en attraktiv läkemedelskandidat att licensiera in för de större läkemedelsbolagen. Pågående fas 1-studie väntas vara klar under första kvartalet 2023 då även top line resultat delges. Det kliniska programmet är planerat att avslutas 2026. |
||||
| 2023-01-16 | Biosergen | Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-12-12 | Biosergen | Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-20 | Biosergen | Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-19 | Biosergen | Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-05 | Biosergen | Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-10-04 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-26 | Biosergen | Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-22 | Biosergen | Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-15 | Biosergen | Biosergen AB: The subscription period in Biosergen's rights issue starts today | Pressreleaser | Visa Stäng |
|
|
||||
| 2022-09-08 | Biosergen | Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-09-02 | Biosergen | Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for second quarter 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-31 | Biosergen | Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-08-26 | Biosergen | Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-07-11 | Biosergen | Biosergen AB: 3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis "Black Fungus" clinical phase II trial. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-30 | Biosergen | Biosergen AB: Biosergen successfully completes second cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-28 | Biosergen | Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-06-07 | Biosergen | Biosergen AB: Biosergen publishes 2021 Annual report | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2022 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2022-05-13 | Biosergen | Biosergen AB: Biosergen successfully completes first cohort of BSG005 phase I trial | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-19 | Biosergen | Biosergen AB: The first subjects dosed successfully with no adverse events in the phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-04-07 | Biosergen | Biosergen AB: The first subject has been dosed in the phase I trial of BSG005 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2022-03-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2021 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
Kommande händelser